RVNC Investors: Leading the Way in Revance Therapeutics, Inc. Securities Fraud
Investors who have purchased shares of Revance Therapeutics, Inc. have the opportunity to participate in a securities fraud lawsuit with the Schall Law Firm. This lawsuit alleges that Revance Therapeutics made false and misleading statements to investors which caused the stock price to be inflated.
The lawsuit claims that Revance Therapeutics made false statements about the effectiveness and market potential of its drug candidate, DaxibotulinumtoxinA for Injection. The company allegedly failed to disclose information about the drug’s deficiencies in the Biologics License Application and the Food and Drug Administration’s concerns about the drug. As a result, investors who purchased shares at inflated prices may have suffered financial losses.
If you purchased shares of Revance Therapeutics during the class period between April 24, 2020 and February 26, 2021, you may be eligible to join the lawsuit. The Schall Law Firm is encouraging investors who have suffered losses to contact them to participate in the lawsuit and recover their losses.
It’s important for investors to be aware of their rights and options in these situations. By participating in the lawsuit, investors have the opportunity to hold Revance Therapeutics accountable for their alleged misconduct and seek compensation for any financial losses suffered as a result of their actions.
